Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr-India News , Technomiz

Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr-India News , Technomiz

The vaccine recently got the nod of approval for phase-3 clinical trials after showing promising results in phase 1 and 2.

Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr

A health worker administers a covid-19 vaccine to a a man during a special vaccination drive held in the premises of a government school in Hyderabad, India, Sunday, May 30, 2021. (AP Photo/Mahesh Kumar A.)

The Union Health Ministry has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore COVID-19 vaccine doses for which it will be making an advance payment of Rs 1500 crore. These vaccine doses will be manufactured and stockpiled by Biological-E from August to December this year, a ministry statement said on Thursday. The COVID-19 vaccine of Biological-E is currently undergoing phase-3 clinical trial after showing promising results in phase 1 and 2 trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months.

The proposal of Biological-E was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC), the statement said.

The arrangement with Biological-E is part of the wider endeavour of the Centre to encourage indigenous vaccine manufacturers by providing them support in research and development and also financial support, it said.

The Biological-E COVID vaccine candidate has been supported by the Centre from preclinical stage to phase-3 studies.

The Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 crore but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad.

See also  India reports less than 1 lakh cases for 10th day

This has been undertaken as part of the government’s ‘Mission COVID Suraksha, the Indian COVID-19 Vaccine Development Mission,’ which was launched to reinforce and accelerate COVID-19 vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0, the statement said.

The mission aims to bring to the citizens a safe, efficacious, affordable and accessible COVID-19 vaccine. The mission is supporting development of 5-6 COVID-19 vaccine candidates. Some of these are now closer to licensure and introduction in public health systems.

It has not just accelerated COVID-19 vaccine development efforts, but also fostered a robust end-to-end vaccine development ecosystem in the country that will be available for other ongoing and future research and developmental activities for other vaccines.

Also read: Hyderabad-based Biological E to manufacture Canadian firm Providence’s COVID 19 vaccine

#Health #ministry #buy #COVID19 #vaccine #doses #BiologicalE #crIndia #News #Technomiz

Leave a Reply

Your email address will not be published. Required fields are marked *